073123_DSL_CME_DiabetesKidney_CMEInfo






Joslin Logo
PQH Logo
New ADA and KDIGO Expert Guidance on the Management of Diabetes: The Role of PCPs in Facilitating Access to Evidence-based Care and Reducing Kidney-Function Decline

Presented by Joslin Diabetes Center in Joint Providership with PlatformQ Health Education, LLC, in collaboration with Kidney Disease: Improving Global Outcomes (KDIGO)

ACKNOWLEDGEMENT

This activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.

TUITION

Complimentary

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Joslin Diabetes Center and PlatformQ Health Education, LLC. Joslin Diabetes Center is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Joslin Diabetes Center designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DATE OF RELEASE/EXPIRATION

The enduring material will be available from July 31, 2023-July 31, 2024.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

  • Discuss strategies to provide people with diabetes access to recommended kidney-function screening
  • Summarize the differences in mechanisms of action between nsMRAs and steroidal MRAs, as well as the safety and efficacy data on nsMRAs and kidney and cardiovascular health in people with type 2 diabetes
  • Explain the rationale for recommending SGLT2 inhibitors for the management of people with type 2 diabetes and kidney disease

INTENDED AUDIENCE

The primary target audience for this activity are US-based primary care physicians, NPs, and PAs. The secondary target audience for this activity are endocrinologists, diabetes educators, nephrologists.

METHOD OF PARTICIPATION

There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the posttest and activity evaluation. It is estimated that these modules will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the posttest.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURES

As part of its accreditation with the Accreditation Council for Continuing Medical Education, Joslin Diabetes Center must disclose to the audience of a Joslin continuing medical education activity the existence of any relevant financial relationships between Joslin and/or its planning and/or CME advisory committee members, speakers, and their spouses/partners and commercial entities. Joslin and its planning and CME advisory committee members and speakers must disclose any relationships they and their spouses/partners have or have had in the prior 12 months with proprietary entities producing healthcare goods or services, with the exception of nonprofit or government organizations and non-healthcare-related companies, which are exempt.

Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fees, honoraria, ownership interests (e.g., stocks, stock options, or other ownership interest, excluding diversified mutual funds), or other financial benefit in any amount. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected.

If a faculty or planning committee member has no information to disclose, this information will also be provided. If a faculty or planning committee member refuses to disclose, he/she will not be able to participate in the planning, management, presentation, or evaluation of any Joslin Diabetes Center CME activity. In addition, faculty have been asked to disclose when a product or device is not labeled for the use under discussion. The opinions and comments expressed in this program are those of the speakers and should not be considered the opinions or comments of Joslin Diabetes Center.

The planners and faculty have reported the following financial relationships with commercial interests. Via Joslin internal review, any relationship deemed relevant to the content of this activity has been identified and resolved through Joslin’s internal processes.

The faculty and planning committee members for this program have disclosed the following:

Faculty

  • Robert C. Stanton, MD*†, Chief, Kidney & Hypertension Section, Joslin Diabetes Center, Associate Professor of Medicine, Harvard Medical School, has no relevant financial relationships
  • Katherine R. Tuttle, MD, FASN, FACP, FNKF, Executive Director for Research, Providence Inland Northwest Health, Professor of Medicine, University of Washington is a consultant for Bayer, Boehringer Ingelheim, Novo Nordisk, and Travere
  • Eugene Edward Wright Jr., MD, Medical Director for Performance Improvement, South Piedmont AHEC, Consulting Associate, Department of Medicine, Duke University Medical Center, is a consultant for Renalytix and a consultant and speaker for Abbott Diabetes Care, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Sanofi

Planning Committee

  • Dr. Richard S. Beaser*, Senior Staff Physician and Medical Director of CME, Joslin Diabetes Center, has no relevant financial relationships with regard to this activity.
  • Vandana Gupta, Medical Director, PlatformQ Health Education, has no relevant financial relationships with regard to this activity.
  • Jaimee Harris-Gold, Program Manager, PlatformQ Health Education, has no relevant financial relationships with regard to this activity.

Joslin CME Advisory Committee

  • Jerry Cavallerano, OD, Optometrist, Beetham Eye Institute, Joslin Diabetes Center, has no relevant financial relationships.
  • Erin Kelly, M.Ed., RN, BSN, CDE, Adult Diabetes Educator, Joslin Diabetes Center, holds stock in Tandem Diabetes Care.
  • Lyle Mitzner, MD, Staff Physician, Joslin Diabetes Center, is a consultant for Conversa Health.
  • Robert C. Stanton, MD, Chief of Nephrology, Joslin Diabetes Center, has no relevant financial relationships
  • Elena Toschi, MD, Staff Physician, Joslin Diabetes Center, has no relevant financial relationships.

* Also on the Planning Committee
† Also on the CME Advisory Committee

CONTACT INFORMATION

Please send content inquiries to: medical.education@joslin.harvard.edu

For technical problems with the site or issues with your CME Certificate, please contact DiabetesSeriesLive at 877-394-1306 or at Support@DiabetesSeriesLive.com.

DISCLAIMERS (if applicable):

The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, health care professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by Joslin Diabetes Center, CardioCareLive, DiabetesSeriesLive, PlatformQ Health Education, LLC or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.